Copyright Reports & Markets. All rights reserved.

Global Nucleotide-based Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Nucleotide-based Therapeutics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Nucleotide-based Therapeutics by Type
    • 1.3.1 Overview: Global Nucleotide-based Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Nucleotide-based Therapeutics Consumption Value Market Share by Type in 2022
    • 1.3.3 Antisense Oligonucleotides (ASO)
    • 1.3.4 siRNA
    • 1.3.5 mRNA
  • 1.4 Global Nucleotide-based Therapeutics Market by Application
    • 1.4.1 Overview: Global Nucleotide-based Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Neuromuscular Diseases
    • 1.4.3 hATTR
    • 1.4.4 COVID-19
    • 1.4.5 Other
  • 1.5 Global Nucleotide-based Therapeutics Market Size & Forecast
  • 1.6 Global Nucleotide-based Therapeutics Market Size and Forecast by Region
    • 1.6.1 Global Nucleotide-based Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Nucleotide-based Therapeutics Market Size by Region, (2018-2029)
    • 1.6.3 North America Nucleotide-based Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Nucleotide-based Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Nucleotide-based Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.6 South America Nucleotide-based Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Nucleotide-based Therapeutics Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Sarepta Therapeutics
    • 2.1.1 Sarepta Therapeutics Details
    • 2.1.2 Sarepta Therapeutics Major Business
    • 2.1.3 Sarepta Therapeutics Nucleotide-based Therapeutics Product and Solutions
    • 2.1.4 Sarepta Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Sarepta Therapeutics Recent Developments and Future Plans
  • 2.2 Ionis Pharmaceuticals
    • 2.2.1 Ionis Pharmaceuticals Details
    • 2.2.2 Ionis Pharmaceuticals Major Business
    • 2.2.3 Ionis Pharmaceuticals Nucleotide-based Therapeutics Product and Solutions
    • 2.2.4 Ionis Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Ionis Pharmaceuticals Recent Developments and Future Plans
  • 2.3 Alnylam
    • 2.3.1 Alnylam Details
    • 2.3.2 Alnylam Major Business
    • 2.3.3 Alnylam Nucleotide-based Therapeutics Product and Solutions
    • 2.3.4 Alnylam Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Alnylam Recent Developments and Future Plans
  • 2.4 Biogen
    • 2.4.1 Biogen Details
    • 2.4.2 Biogen Major Business
    • 2.4.3 Biogen Nucleotide-based Therapeutics Product and Solutions
    • 2.4.4 Biogen Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Biogen Recent Developments and Future Plans
  • 2.5 Nippon Shinyaku
    • 2.5.1 Nippon Shinyaku Details
    • 2.5.2 Nippon Shinyaku Major Business
    • 2.5.3 Nippon Shinyaku Nucleotide-based Therapeutics Product and Solutions
    • 2.5.4 Nippon Shinyaku Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Nippon Shinyaku Recent Developments and Future Plans
  • 2.6 Sobi
    • 2.6.1 Sobi Details
    • 2.6.2 Sobi Major Business
    • 2.6.3 Sobi Nucleotide-based Therapeutics Product and Solutions
    • 2.6.4 Sobi Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Sobi Recent Developments and Future Plans
  • 2.7 Novartis
    • 2.7.1 Novartis Details
    • 2.7.2 Novartis Major Business
    • 2.7.3 Novartis Nucleotide-based Therapeutics Product and Solutions
    • 2.7.4 Novartis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Novartis Recent Developments and Future Plans
  • 2.8 BioNTech
    • 2.8.1 BioNTech Details
    • 2.8.2 BioNTech Major Business
    • 2.8.3 BioNTech Nucleotide-based Therapeutics Product and Solutions
    • 2.8.4 BioNTech Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 BioNTech Recent Developments and Future Plans
  • 2.9 Pfizer
    • 2.9.1 Pfizer Details
    • 2.9.2 Pfizer Major Business
    • 2.9.3 Pfizer Nucleotide-based Therapeutics Product and Solutions
    • 2.9.4 Pfizer Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Pfizer Recent Developments and Future Plans
  • 2.10 Moderna Therapeutics
    • 2.10.1 Moderna Therapeutics Details
    • 2.10.2 Moderna Therapeutics Major Business
    • 2.10.3 Moderna Therapeutics Nucleotide-based Therapeutics Product and Solutions
    • 2.10.4 Moderna Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Moderna Therapeutics Recent Developments and Future Plans
  • 2.11 Jazz Pharmaceuticals
    • 2.11.1 Jazz Pharmaceuticals Details
    • 2.11.2 Jazz Pharmaceuticals Major Business
    • 2.11.3 Jazz Pharmaceuticals Nucleotide-based Therapeutics Product and Solutions
    • 2.11.4 Jazz Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Jazz Pharmaceuticals Recent Developments and Future Plans
  • 2.12 CureVac
    • 2.12.1 CureVac Details
    • 2.12.2 CureVac Major Business
    • 2.12.3 CureVac Nucleotide-based Therapeutics Product and Solutions
    • 2.12.4 CureVac Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 CureVac Recent Developments and Future Plans
  • 2.13 Regulus Therapeutics
    • 2.13.1 Regulus Therapeutics Details
    • 2.13.2 Regulus Therapeutics Major Business
    • 2.13.3 Regulus Therapeutics Nucleotide-based Therapeutics Product and Solutions
    • 2.13.4 Regulus Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Regulus Therapeutics Recent Developments and Future Plans
  • 2.14 ProQR
    • 2.14.1 ProQR Details
    • 2.14.2 ProQR Major Business
    • 2.14.3 ProQR Nucleotide-based Therapeutics Product and Solutions
    • 2.14.4 ProQR Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 ProQR Recent Developments and Future Plans
  • 2.15 Secarna
    • 2.15.1 Secarna Details
    • 2.15.2 Secarna Major Business
    • 2.15.3 Secarna Nucleotide-based Therapeutics Product and Solutions
    • 2.15.4 Secarna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 Secarna Recent Developments and Future Plans
  • 2.16 MiNA Therapeutics
    • 2.16.1 MiNA Therapeutics Details
    • 2.16.2 MiNA Therapeutics Major Business
    • 2.16.3 MiNA Therapeutics Nucleotide-based Therapeutics Product and Solutions
    • 2.16.4 MiNA Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.16.5 MiNA Therapeutics Recent Developments and Future Plans
  • 2.17 Sylentis
    • 2.17.1 Sylentis Details
    • 2.17.2 Sylentis Major Business
    • 2.17.3 Sylentis Nucleotide-based Therapeutics Product and Solutions
    • 2.17.4 Sylentis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.17.5 Sylentis Recent Developments and Future Plans
  • 2.18 Arrowhead
    • 2.18.1 Arrowhead Details
    • 2.18.2 Arrowhead Major Business
    • 2.18.3 Arrowhead Nucleotide-based Therapeutics Product and Solutions
    • 2.18.4 Arrowhead Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.18.5 Arrowhead Recent Developments and Future Plans
  • 2.19 Silence Therapeutics
    • 2.19.1 Silence Therapeutics Details
    • 2.19.2 Silence Therapeutics Major Business
    • 2.19.3 Silence Therapeutics Nucleotide-based Therapeutics Product and Solutions
    • 2.19.4 Silence Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.19.5 Silence Therapeutics Recent Developments and Future Plans
  • 2.20 Dicerna
    • 2.20.1 Dicerna Details
    • 2.20.2 Dicerna Major Business
    • 2.20.3 Dicerna Nucleotide-based Therapeutics Product and Solutions
    • 2.20.4 Dicerna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.20.5 Dicerna Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Nucleotide-based Therapeutics Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Nucleotide-based Therapeutics by Company Revenue
    • 3.2.2 Top 3 Nucleotide-based Therapeutics Players Market Share in 2022
    • 3.2.3 Top 6 Nucleotide-based Therapeutics Players Market Share in 2022
  • 3.3 Nucleotide-based Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Nucleotide-based Therapeutics Market: Region Footprint
    • 3.3.2 Nucleotide-based Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Nucleotide-based Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Nucleotide-based Therapeutics Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Nucleotide-based Therapeutics Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Nucleotide-based Therapeutics Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Nucleotide-based Therapeutics Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Nucleotide-based Therapeutics Consumption Value by Type (2018-2029)
  • 6.2 North America Nucleotide-based Therapeutics Consumption Value by Application (2018-2029)
  • 6.3 North America Nucleotide-based Therapeutics Market Size by Country
    • 6.3.1 North America Nucleotide-based Therapeutics Consumption Value by Country (2018-2029)
    • 6.3.2 United States Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Nucleotide-based Therapeutics Consumption Value by Type (2018-2029)
  • 7.2 Europe Nucleotide-based Therapeutics Consumption Value by Application (2018-2029)
  • 7.3 Europe Nucleotide-based Therapeutics Market Size by Country
    • 7.3.1 Europe Nucleotide-based Therapeutics Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.3 France Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Nucleotide-based Therapeutics Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Nucleotide-based Therapeutics Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Nucleotide-based Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Nucleotide-based Therapeutics Consumption Value by Region (2018-2029)
    • 8.3.2 China Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.5 India Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Nucleotide-based Therapeutics Consumption Value by Type (2018-2029)
  • 9.2 South America Nucleotide-based Therapeutics Consumption Value by Application (2018-2029)
  • 9.3 South America Nucleotide-based Therapeutics Market Size by Country
    • 9.3.1 South America Nucleotide-based Therapeutics Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Nucleotide-based Therapeutics Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Nucleotide-based Therapeutics Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Nucleotide-based Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Nucleotide-based Therapeutics Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Nucleotide-based Therapeutics Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Nucleotide-based Therapeutics Market Drivers
  • 11.2 Nucleotide-based Therapeutics Market Restraints
  • 11.3 Nucleotide-based Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Nucleotide-based Therapeutics Industry Chain
  • 12.2 Nucleotide-based Therapeutics Upstream Analysis
  • 12.3 Nucleotide-based Therapeutics Midstream Analysis
  • 12.4 Nucleotide-based Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Nucleotide-based Therapeutics market size was valued at USD 65800 million in 2022 and is forecast to a readjusted size of USD 84010 million by 2029 with a CAGR of 3.6% during review period.
    Nucleotide-based therapeutics offer huge potential to specifically modulate cellular pathways in ways not previously possible. These therapies include all nucleic-acid-based approaches that work inside cells to affect gene expression – the genetic blueprint of disease – to ultimately change protein expression and potentially alter the course of disease.
    The Nucleic Acid-Based Therapeutics Drug Market is driven by the promising potential of nucleic acid-based therapies in treating various genetic and acquired diseases, including genetic disorders, cancer, and infectious diseases. These innovative drugs utilize nucleic acids, such as DNA or RNA, to modify or regulate gene expression, correct genetic mutations, or target specific disease-associated genes. As the understanding of genomics and molecular biology advances, and personalized medicine gains traction, the demand for nucleic acid-based therapeutics continues to grow. Innovations in drug development, delivery systems, and gene editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to address delivery and stability issues, ensure long-term safety and efficacy, and navigate regulatory complexities and patient acceptance. Overcoming technical and scientific hurdles, optimizing drug delivery methods, and addressing concerns about off-target effects are ongoing challenges. Additionally, the market faces competition from conventional therapies and the need for continuous research and development to unlock the full therapeutic potential of nucleic acid-based drugs. Striking a balance between providing safe, effective, and accessible nucleic acid-based therapeutics while addressing scientific and regulatory challenges is essential for the continued growth of the Nucleic Acid-Based Therapeutics Drug Market.
    The Global Info Research report includes an overview of the development of the Nucleotide-based Therapeutics industry chain, the market status of Neuromuscular Diseases (Antisense Oligonucleotides (ASO), siRNA), hATTR (Antisense Oligonucleotides (ASO), siRNA), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Nucleotide-based Therapeutics.
    Regionally, the report analyzes the Nucleotide-based Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Nucleotide-based Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Nucleotide-based Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Nucleotide-based Therapeutics industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Antisense Oligonucleotides (ASO), siRNA).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Nucleotide-based Therapeutics market.
    Regional Analysis: The report involves examining the Nucleotide-based Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Nucleotide-based Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Nucleotide-based Therapeutics:
    Company Analysis: Report covers individual Nucleotide-based Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Nucleotide-based Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Neuromuscular Diseases, hATTR).
    Technology Analysis: Report covers specific technologies relevant to Nucleotide-based Therapeutics. It assesses the current state, advancements, and potential future developments in Nucleotide-based Therapeutics areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Nucleotide-based Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Nucleotide-based Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
    Market segment by Type
    Antisense Oligonucleotides (ASO)
    siRNA
    mRNA
    Market segment by Application
    Neuromuscular Diseases
    hATTR
    COVID-19
    Other
    Market segment by players, this report covers
    Sarepta Therapeutics
    Ionis Pharmaceuticals
    Alnylam
    Biogen
    Nippon Shinyaku
    Sobi
    Novartis
    BioNTech
    Pfizer
    Moderna Therapeutics
    Jazz Pharmaceuticals
    CureVac
    Regulus Therapeutics
    ProQR
    Secarna
    MiNA Therapeutics
    Sylentis
    Arrowhead
    Silence Therapeutics
    Dicerna
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Nucleotide-based Therapeutics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Nucleotide-based Therapeutics, with revenue, gross margin and global market share of Nucleotide-based Therapeutics from 2018 to 2023.
    Chapter 3, the Nucleotide-based Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Nucleotide-based Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Nucleotide-based Therapeutics.
    Chapter 13, to describe Nucleotide-based Therapeutics research findings and conclusion.

    Buy now